Dark

MREO
Mereo BioPharma Group plc
stock NASDAQ ADR

Market Open

Mar 17, 2026 11:28:52 AM EDT

0.3900USD-3.134%(-0.0125)682,758

0.3800Bid 0.3900Ask 0.0100Spread

Pre-market

Mar 17, 2026 9:20:30 AM EDT

0.3909USD-2.006%(-0.0080)63,482

After-hours

Mar 16, 2026 4:08:30 PM EDT

0.3999USD-0.671%(-0.0027)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Dec 22, 2021

12:46PM EST Mereo BioPharma's Alvelestat Shows Improvement In COVID-19 Severity Benzinga

07:10AM EST UAB And Mereo Announce Top-Line Results From COSTA Phase 1b/2 Trial Of Alvelestat (MPH966) In Hospitalized Patients With COVID-19 Respiratory Disease; Says 'Alvelestat reported safe and well-tolerated in patients with COVID-19' Benzinga

07:00AM EST UAB and Mereo Announce Positive Top-line Results from GlobeNewswire Inc

Dec 13, 2021

07:21AM EST Biomarker Data From Phase 1b/2 Investigator-sponsored Trial Of Mereo's Alvelestat In Bronchiolitis Obliterans Syndrome At The ASH Annual Meeting Benzinga

07:00AM EST Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of GlobeNewswire Inc

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Nov 30, 2021

04:58PM EST Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer Benzinga

04:43PM EST Mereo BioPharma Reports Interim Data From ACTIVATE Phase 1b/2 Open Label Study Of Etigilimab Anti-TIGIT Antibody In Combination With Nivolumab In Solid Tumors; Says 'Etigilimab was well tolerated with a favorable safety profile' Benzinga

07:12AM EST Mereo BioPharma Reports Promising Interim Data From ACTIVATE Study In Solid Tumors RTTNews

07:00AM EST One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set GlobeNewswire Inc

Nov 9, 2021

08:00AM EST Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will present at two upcoming investor conferences: GlobeNewswire Inc

Oct 26, 2021

08:13AM EDT Mereo BioPharma Receives US Orphan Drug Designation For Alvelestat In The Treatment Of Alpha-1 Antitrypsin Deficiency Benzinga

08:00AM EDT Mereo BioPharma Group plc (NASDAQ: MREO), Mereo or the Company, a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alvelestat for the treatment of alpha-1 antitrypsin deficiency (AATD). GlobeNewswire Inc

Oct 13, 2021

08:00AM EDT Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe GlobeNewswire Inc

Oct 1, 2021

04:38PM EDT Mereo BioPharma And Ultragenyx Present Data From Phase 2b ASTEROID Study Of UX143 (setrusumab) In Osteogenesis Imperfecta (OI) At American Society For Bone And Mineral Research (ASBMR) 2021 Annual Meeting Benzinga

04:31PM EDT Previously reported data demonstrated dose-dependent, statistically significant bone-building effect at multiple anatomical sites in adult patients with OI that was consistent across subtypes of OI GlobeNewswire Inc

Sep 20, 2021

08:00AM EDT Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., GlobeNewswire Inc

Sep 9, 2021

Aug 2, 2021

08:00AM EDT Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 9:30am Eastern Time. GlobeNewswire Inc

Jun 2, 2021

09:45AM EDT Mereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome Benzinga

08:19AM EDT Mereo BioPharma Highlights Biomarker Data From Interim Analysis For Bronchiolitis Obliterans Syndrome Study Candidate Benzinga

08:09AM EDT Mereo Reports Positive Data From Interim Analysis Of Investigator-initiated Study Of Alvelestat RTTNews

08:00AM EDT Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced positive data from an interim analysis of an investigator-initiated study of alvelestat in patients with Bronchiolitis Obliterans Syndrome (BOS) following hematopoietic stem cell transplantation (HCT). GlobeNewswire Inc

May 27, 2021

08:00AM EDT Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Thursday, June 3, 2021 at 8:00am Eastern Time. GlobeNewswire Inc

May 5, 2021

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2021 Benzinga

09:32AM EDT BTIG Initiates Coverage On Mereo BioPharma Group with Buy Rating, Announces Price Target of $10 Benzinga

May 4, 2021

08:00AM EDT Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021 GlobeNewswire Inc

Apr 30, 2021

09:24AM EDT Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab Benzinga

08:04AM EDT Mereo BioPharma Reports Partnership with Cancer Focus For Phase 1b/2 Study Of Etigilimab In Clear Cell Ovarian Cancer Benzinga

08:00AM EDT Mereo BioPharma and Cancer Focus Fund Announce Partnership for GlobeNewswire Inc

Apr 8, 2021

08:30AM EDT Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Company management will present at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 11:00am Eastern Time. GlobeNewswire Inc

Apr 5, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2021 Benzinga

07:14AM EDT Needham Initiates Coverage On Mereo BioPharma Group with Buy Rating, Announces Price Target of $10 Benzinga

Mar 31, 2021

05:07PM EDT Mereo BioPharma Reports FY20 EPS $(0.48) Down From $(0.39) YoY Benzinga

05:02PM EDT -- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta --- Further Strengthened Management Team --- OncXerna Global Licensing Agreement for Navicixizumab --- Strengthened Balance Sheet through Public and Private Financings and Business Development Transactions -- GlobeNewswire Inc

Mar 2, 2021

10:28AM EST Mereo BioPharma Awarded Patent Titled 'Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide' Benzinga

Mar 1, 2021

05:31PM EST Mereo Biopharma 13G Filing From Point72 Shows New 6.4% Stake In Co. Benzinga

Feb 23, 2021

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

Feb 19, 2021

07:25AM EST The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko Benzinga

Feb 18, 2021

07:00AM EST Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the 10thAnnual SVBLeerinkGlobal Healthcare Conference on Thursday, February 25, 2021 at 8:00am Eastern Time. GlobeNewswire Inc

Feb 17, 2021

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 12, 2021

12:41PM EST Mereo BioPharma Group plc Announces Closing of Public Offering of GlobeNewswire Inc

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

07:00AM EST Mereo BioPharma Group plc Announces Pricing of Public Offering of GlobeNewswire Inc

Feb 9, 2021

04:03PM EST Mereo BioPharma Reports Offering Of Common Shares, No Size Disclosed Benzinga

04:03PM EST Mereo BioPharma Group plc Announces Proposed Public Offering of GlobeNewswire Inc

Dec 18, 2020

02:59PM EST Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; Mereo BioPharma Shares Spike Higher Benzinga

12:25PM EST Mid-Day Market Update: Crude Oil Rises 1.5%; Mesoblast Shares Plunge Benzinga

10:24AM EST Shares of Mereo BioPharma Group plc (MREO) are currently surging over 50% after the clinical stage biopharmaceutical company announced a collaboration deal with Ultragenyx Pharmaceutical Inc. (RARE), a company focused on development of treatment for ultra-rare diseases. RTTNews

10:21AM EST Mid-Morning Market Update: Markets Open Lower; Darden Restaurants Reports Upbeat Profit Benzinga

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

Dec 17, 2020

04:07PM EST Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta; Mereo Will Receives $50M Upfront And Is Eligible For Milestones Up To $254M Benzinga

04:05PM EST Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyxs existing bone franchise GlobeNewswire Inc

Dec 15, 2020

01:05PM EST Mereo BioPharma Offers Update On AIM Delisting, Continued Listing On Nasdaq; Issued Added Warrants Related To Deal With Silicon Valley Bank, Kreos Capital V Benzinga

01:00PM EST Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (Mereo or the Company), a clinical stage biopharmaceutical company focused on oncology and rare diseases,today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and the continued listing of its ADSs on Nasdaq, as originally announced on November 11, 2020. GlobeNewswire Inc

Nov 23, 2020

07:10AM EST Mereo BioPharma Appoints Suba Krishnan As SVP Of Clinical Development, Effective December 7, 2020 RTTNews

07:05AM EST Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice GlobeNewswire Inc

Nov 16, 2020

07:00AM EST Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020 GlobeNewswire Inc

Nov 10, 2020

07:23AM EST Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (Mereo or the Company), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am Eastern Time. GlobeNewswire Inc

Oct 20, 2020

07:10AM EDT Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs Benzinga

07:00AM EDT Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (Mereo or the Company), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Christine Fox, CPA, as Chief Financial Officer (CFO) and Heidi Petersen as Senior Vice President, Regulatory Affairs. GlobeNewswire Inc

Oct 19, 2020

07:11AM EDT Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab Benzinga

07:00AM EDT On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020 GlobeNewswire Inc

Oct 6, 2020

04:29PM EDT Mereo BioPharma Filing Shows Registration For $200M ADS Offering Benzinga

Sep 29, 2020

07:00AM EDT On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020 GlobeNewswire Inc

03:40AM EDT Earnings Scheduled For September 29, 2020 Benzinga

Sep 24, 2020

10:20AM EDT Mereo BioPharma Group shares are trading higher after the company announced it received FDA rare pediatric disease designation for its Setrusumab to treat Osteogenesis Imperfecta. Benzinga

07:25AM EDT Mereo BioPharma: FDA Grants Rare Pediatric Disease Designation To Setrusumab RTTNews

07:15AM EDT Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta Benzinga

07:00AM EDT Mereo BioPharma Receives FDA Rare Pediatric Disease Designation GlobeNewswire Inc

Sep 16, 2020

08:00AM EDT Mereo BioPharma to Announce Interim Financial Results for the Six GlobeNewswire Inc

Aug 25, 2020

07:45AM EDT Mereo Begins Phase 1b/2 Trial To Evaluate Alvelestat In RTTNews

07:30AM EDT Mereo BioPharma Begins Phase 1b/2 Clinical Trial With Alvelestat In COVID-19 Respiratory Disease RTTNews

07:16AM EDT Mereo Begins Placebo-Controlled Phase 1b/2 Trial With Alvelestat In COVID-19 Respiratory Disease RTTNews

07:13AM EDT Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease Benzinga

07:00AM EDT Mereo BioPharma Announces Initiation of Placebo-Controlled Phase GlobeNewswire Inc

.dark-mode .xjdVtP{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .xjdVtP{ color: #333333; background-color: white; border: 2px solid #333333; }MREOMereo BioPharma Group plcstock NASDAQ ADR

MREO
Mereo BioPharma Group plc
stock NASDAQ ADR